Peripheral T-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Peripheral T-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2012-09-07Clinical Trial Update: Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL [Phase 1]
Phase I study of KW-0761 (mogamulizumab) in relapsed CCR4-positive adult T-cell leukemia/lymphoma and peripheral T-cell lymphoma; results ha…
-
CLINICAL_TRIALS trial_result · 2012-09-06Clinical Trial Update: Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma [Phase 2]
Phase 2 trial evaluating intensive chemo-immunotherapy as first-line treatment in adults with peripheral T-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2012-08-27Clinical Trial Update: Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Patients [Phase 2]
A Phase 2 trial evaluating lenalidomide in relapsed/refractory peripheral T-cell lymphoma has been terminated.
-
CLINICAL_TRIALS trial_result · 2012-08-13Clinical Trial Update: A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma [Phase 2]
A Phase 2 clinical trial of romidepsin for progressive or relapsed peripheral T-cell lymphoma has completed with results posted in 2012.
-
FDA approval · 2012-05-30FDA Approved: FOLOTYN — Supplemental Application (Acrotech Biopharma Inc)
FDA approves a supplemental application for FOLOTYN (pralatrexate) submitted by Acrotech Biopharma Inc., granting an additional regulatory a…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2012-05-07Clinical Trial Update: Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP [Phase 3]
A Phase 3 clinical trial evaluating adding alemtuzumab to dose-dense CHOP for peripheral T-cell lymphomas, including angioimmunoblastic T-ce…
-
CLINICAL_TRIALS trial_result · 2012-04-20Clinical Trial Update: Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas [EARLY_Phase 1]
An early-phase 1 study of lenalidomide in relapsed and/or refractory peripheral T-cell lymphomas was terminated.
-
FDA approval · 2012-02-15FDA Approved: FOLOTYN — Supplemental Application (Acrotech Biopharma Inc)
FDA approved a supplemental application for Folotyn (pralatrexate) submitted by Acrotech Biopharma Inc.
-
CLINICAL_TRIALS research · 2011-11-11Clinical Trial Update: Clinical Usefulness and Prognostic Significance of Interim 18F-FDG PET/CT for the Treatment of Peripheral T Cell Lymphomas
This clinical trial update assesses the usefulness and prognostic value of interim 18F-FDG PET/CT imaging in the treatment of peripheral T-c…
-
CLINICAL_TRIALS trial_result · 2011-10-06Clinical Trial Update: The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL) [Phase 2]
Phase 2 trial assessing the effectiveness of adding alemtuzumab to CHOP and ESHAP regimens in newly diagnosed Peripheral T-cell lymphoma; th…
-
CLINICAL_TRIALS trial_result · 2011-09-08Clinical Trial Update: A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT [Phase 2]
This completed Phase II trial in peripheral T-cell lymphoma evaluated dose-intensive induction followed by high-dose consolidation with auto…
-
FDA approval · 2011-04-12FDA Approved: ISTODAX — Supplemental Application (Celgene Corporation)
The FDA approved a supplemental application for Istodax (romidepsin) submitted by Celgene Corporation.
-
FDA approval · 2011-01-07FDA Approved: FOLOTYN — Supplemental Application (Acrotech Biopharma Inc)
FDA approved a supplemental application for FOLOTYN (pralatrexate) from Acrotech Biopharma Inc.
-
CLINICAL_TRIALS trial_result · 2010-09-15Clinical Trial Update: Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma [Phase 2]
Phase 2 trial update evaluating Endostar in combination with CHOP as first-line chemotherapy for peripheral T cell lymphoma; no results are …
-
CLINICAL_TRIALS research · 2010-09-15Clinical Trial Update: Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed Peripheral T-cell Lymphomas (PTCL) [Phase 2]
A Phase 2 clinical trial evaluating the oral Fludarabine, Adriamycin (doxorubicin), and Dexamethasone (FAD) regimen for newly diagnosed Peri…
-
FDA approval · 2010-04-26FDA Approved: FOLOTYN — Supplemental Application (Acrotech Biopharma Inc)
FDA approved a supplemental application for FOLOTYN (pralatrexate) from Acrotech Biopharma Inc, updating the product labeling.
-
CLINICAL_TRIALS trial_result · 2010-02-01Clinical Trial Update: Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma [Phase 2]
A Phase 2 trial evaluating pralatrexate with vitamins B12 and folic acid in relapsed or refractory peripheral T-cell lymphoma has completed …
-
CLINICAL_TRIALS trial_result · 2009-12-11Clinical Trial Update: LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma [NA]
The LAMPP trial studying peripheral and cutaneous T-cell lymphoma has been terminated.
-
CLINICAL_TRIALS trial_result · 2009-10-14Clinical Trial Update: Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas [Phase 1, Phase 2]
A completed Phase 1/2 clinical study evaluated combining bortezomib with CHOP chemotherapy in patients with advanced aggressive T-cell lymph…
-
FDA approval · 2009-09-24FDA Approved: FOLOTYN — Original Application (Acrotech Biopharma Inc)
FDA approved Folotyn (pralatrexate) as an initial approval for relapsed or refractory peripheral T-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2009-09-09Clinical Trial Update: Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma [Phase 3]
A Phase 3 clinical trial evaluating treatment for newly diagnosed non-cutaneous peripheral T-cell lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2009-06-25Clinical Trial Update: The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL [Phase 2]
Phase 2 trial evaluating the effectiveness of alemtuzumab combined with CHOP in newly diagnosed peripheral T-cell lymphoma; the study status…